


Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET

1

OF

5

*Complete If Known*

Application Number - 10/005,438

Filing Date - Dec. 3, 2001

First Named Inventor - Tse Wen Chang

Group Art Unit - 1642

Examiner Name - S. UNGAR

Attorney Docket Number TNX95-2ABB

### U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number Code	Kind (if known)			
	4973478	B1	Gauldie, et al.	05/24/1989	
	5004605	B1	Hershenson, et al.	04/02/1991	
	5460811	B1	Goeddel, et al.	10/24/1995	
D	5468803	B1	Revel, et al.	11/21/1995	
	5468804	B1	Revel, et al.	11/21/1995	
	5468607	B1	Revel, et al.	11/21/1995	

### FOREIGN DOCUMENTS

Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	Office	Number	Kind Code (if known)				
D	EP	0063069	B1	Illich, et al.	08/11/1987		
	EP	0064681	A2	Taniguchi, et al.	11/17/1982		
	EP	0407410	A1	Burnett, et al.	01/22/1992		
	WO	0118353	A1	Varocchi, et al.	10/31/1991		

Examiner Signature

*Susan Clark*

Date Considered

4/12/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<i>Complete if Known</i>	
SHEET	2	OF	5
		Application Number 10/005,438	
		Filing Date Dec. 3, 2001	
		First Named Inventor - Tse Wen Chang	
		Group Art Unit 1642	
		Examiner Name S. UNGAR	
		Attorney Docket Number TNX95-2ABB	

U.S. PATENT DOCUMENTS					
Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number Code	Kind (if known)			
	5015730	-B1-	Friesen, et al.	05/14/1991	DUPPLICATE
	4289689	-B1-	Friesen, et al.	09/15/1981	Duplicate
	5428430	-B1-	Capon, et al.	08/27/1995	7.1
	5348053	-B1-	Landoil	09/20/1994	Duplicate

FOREIGN DOCUMENTS					
Examiner Initials	Foreign Patent Documents		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Office	Number	Kind Code (if known)		

Examiner Signature	<i>Susan Clark</i>	Date Considered	4/12/06
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

3

OF

5

*Complete if Known*

Application Number 10/005,438

Filing Date Dec. 3, 2001

First Named Inventor Tse Wen Chang

Group Art Unit 1642

Examiner Name S. UNGAR

Attorney Docket Number TNX95-2ABB

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T 2
		<del>Huston, J.S. et al., Methods in Enzymology, 203:46-88</del>	
<i>SL</i>		Landolfi, N.F., <i>J. Immunol.</i> , 146:915-919 (1991), Chimeric IL-2/Ig Molecule.	
		<del>Peterhans, A., et al., Analytical Biochemistry, 163(2):470-75</del>	
<i>SL</i>		Bafon, E. and Narula S., <i>Biotechnology</i> , 10:179-190, 1990, From cloning to a commercial realization: Human alpha interferon.	
		Bocci, V., <i>Interferon</i> , 4:47-72, 1985, Distribution, catabolism and pharmacokinetics of interferons.	
		Bohoslawiec, O. et al., <i>J. Interferon Res.</i> , 6:207-213, 1986, Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in Mice.	
		Bonetti, A. and Kim, S. <i>Cancer Chemother Pharmacol.</i> 33:258-261, 1993, Pharmacokinetics of an extended-release human interferon alpha-2b formulation.	
		Brown, K.D. <i>Genetic Engineering News</i> , 15:1-35, 1995, Novel emerging therapeutics target the hepatitis C virus.	
		Brunt, J.V., <i>Biotechnology</i> , 7:549, 1989, Interferon trials proliferate.	
		Cantell, K. et al., <i>Methods in Enzymology</i> , 78A:29-38, Academic Press, 1981.	
		Coligan, J.E. et al., <i>Current Protocols in Immunology</i> , pp 6.9.1-6.9.8, Current Protocols, 1991, Measurement of antiviral activity induced by interferon $\alpha$ , $\beta$ , and $\gamma$ .	
		Daugherty, B.L. et al., <i>Nucleic Acids Res.</i> 19:2471-6, 1991, Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins.	
<i>SL</i>		Dianzani, F. <i>J. Interferon Res. (Special Issue)</i> 109-118, 1992, Interferon treatments: how to use an endogenous system as a therapeutic agent.	
Examiner Signature		<i>Susan Clark</i>	Date Considered 4/12/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

4

OF

5

*Complete if Known*

Application Number 10/005,438

Filing Date Dec. 3, 2001

First Named Inventor Tse Wen Chang

Group Art Unit 1642

Examiner Name S. UNGAR

Attorney Docket Number TNX95-2ABB

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T 2
<i>8x</i>	-	Evinger, M. and Pestka, S., <i>Methods in Enzymology</i> , 79:362-8, Assay of growth inhibition in lymphoblastoid cell cultures.	
		Goeddel, D.V. et al., <i>Nature</i> , 290:20-26, 1981, The structure of eight distinct cloned human leukocyte interferon dDNAs	
		Guterman, J., <i>Proc. Nat. Aca. Sci.</i> 91:1198-1205;1994, Cytokine therapeutics: lessons from interferon $\alpha$ .	
		Johns, T.G. et al., <i>Cancer Res.</i> , 50:4718-23, 1990, Pharmacokinetics, tissue distribution, and cell localization of [ $^{35}$ S] methionine-labeled recombinant human and murine $\alpha$ interferons in mice.	
		Kabat, E.A. et al., <i>Sequences of proteins of immunological interest</i> , pp 1582-98, NIH, 1991	
		Kurschner, C. et al., <i>J. Immunol.</i> 149:4096-4100, 1992, IFN- $\gamma$ receptor-Ig fusion proteins.	
		Mordini, J. et al., <i>Nature</i> , 337:525-31, 1989, Designing CD4 immunoadhesins for AIDS therapy.	
		Quesada, J.R. et al., <i>J. Clin. Oncol.</i> 4:234-243, 1986, Clinical toxicity of interferons in cancer patients: a review	
		Roche Labs, Referon A, Schering, Intron A, <i>Physicians' Desk Reference</i> , 47 edition, 1993, pp. 2006-2008, 2194-2201.	
		Roitt, I., <i>Essential Immunology</i> , 7 <sup>th</sup> edition, 1991, Blackwell Scientific Publications, pp. 45-51, Immunoglobulin classes and subclasses.	
		Saiki, R.K. et al., <i>Science</i> , 239:487, 1988, Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.	
		Sambrook, J. et al., <i>Molecular cloning</i> , 1989, Cold Spring Harbor Laboratory Press, pp. 16.28-16.29.	
<i>4x</i>	1	Schein, C.H. and Noteborn, H.M., <i>Bio/technology</i> , 6:291-294, 1988, Formation of soluble recombinant proteins in <i>Escherichia coli</i> is favored by lower growth temperature.	
Examiner Signature	<i>Byan Clark</i>		Date Considered 4/12/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

5

OF

5

*Complete if Known*

Application Number 10/005,438

Filing Date Dec. 3, 2001

First Named Inventor Tse Wen Chang

Group Art Unit 1642

Examiner Name S. UNGAR

Attorney Docket Number TNX95-2ABB

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sub>2</sub>
<i>SL</i>		Scorer, C.A. et al., Gene, 136:111-9, 1993, The intracellular production and secretion of HIV-1 envelope protein in the methylotrophic yeast <i>Pichia pastoris</i> .	
<i>SL</i>		Strander, H. <i>Adv. Cancer Res.</i> 46:1-265, 1986, Interferon treatment of human neoplasia.	
<i>SL</i>		Tabata, Y. et al., <i>Cancer Res.</i> 51:5532-8, 1991, Effects of recombinant alpha-interferon-gelatin conjugate on in vivo murine tumor cell growth.	
<i>SL</i>		Von Gabain, A., et al., <i>Eur. J. Biochem.</i> 190:257-61, 1990, Three human interferon- $\alpha$ 2 subvariants disclose structural and functional differences.	
<i>SL</i>		Weissmann, C. and Weber, H. <i>Prog. Nuc. Acid Res. Mol. Biol.</i> 33:251-300, 1986, The interferon genes. <i>PLoS</i> <i>bioRxiv</i>	
<i>SL</i>		Wilkinson, D.L. and Harrison, R.G., <i>Bio/technology</i> , 9:443-448, 1991, Predicting the solubility of recombinant proteins in <i>Escherichia coli</i> .	
<i>SL</i>		Zoon, K.C. <i>Interferon</i> , 9:1-12, 1987, Human interferons: structure and function.	
<i>SL</i>		Physicians' Desk Reference 2194-2201	
<i>SL</i>		Capon, D. et al., <i>Nature</i> , 337:525-531, 1989, Designing CD4 Immunoadhesions for AIDS Therapy	
Examiner Signature		<i>Susan Clark</i>	Date Considered 4/12/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.